We create innovative treatments for nervous system damage due to injury or disease.
NervGen Pharma
NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial. The company’s lead target indication is spinal cord injury.
Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury
NervGen is actively recruiting for a landmark Phase 1b/2a proof-of-concept clinical trial of
NVG-291 in individuals with spinal cord injury.
For information regarding recruitment, the call center phone number is +1 (855) 559-6902.
View our Corporate Presentation
Stay Connected
Subscribe to our mailing list to stay up to date
The Latest
News Release
April 17, 2024
NervGen reported its financial and operational results for the year ended December 31, 2023.
News Release
February 15, 2024
NervGen announced it's on track to complete enrollment in Q2 2024 and deliver the data readout in Q3 2024 of the chronic cohort in it’s Phase 1b/2a proof-of-concept, double blind, randomized placebo-controlled clinical trial for NVG-291 in individuals with spinal cord injury.
Article
July 28, 2022
Unlike existing treatments that focus on rehabilitation or reducing the risk of an additional stroke, the experimental drug targets the "stickiness" that can prevent injured brain tissue from functioning as it should